NHS Long Term Plan 2020 - Partner Profile - Norgine
Updated: Nov 28, 2019
Who are Norgine?
Across the globe in 2018, Norgine is proud to have helped 23 million patients.
Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. We understand the complexities of the European healthcare systems and have a direct presence in 14 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets.
We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world.
In 2012, Norgine established a complementary business, Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US.
For more information, please visit www.norgineventures.com
NORGINE and the sail logo are trademarks of the Norgine group of companies.
How has Norgine improved outcomes for the NHS and patients?
Norgine strive to provide medicines / products that deliver real change to the patient experience as well as improve outcomes for the NHS. We have delivered NICE recommended medicines and devices to the NHS in England, delivering cost-effective treatments to patients. These products, in addition to the remainder of our portfolio, help support the Long Term Plan, through:
· Efficiency in the provision of health services
· Reduction of pressure on emergency services
· Provision of care outside of hospital
We have developed bowel preparations that ensure that colonoscopies are carried out as efficiently as possible and improve visualisation to enhance diagnosis for the patient.
For the past 20 years we have delivered a number of options for the management of constipation which if left untreated can have a major impact on patients, their carers as well as placing a burden on the NHS.
Norgine’s licensing model brings medicines to the NHS that otherwise may not reach patients in the UK.
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
The inclusion of Norgine in the ITP was a landmark for the company and patients. This led to collaboration with NHSE on training and ensuring patients have access to an innovative product. This successful partnership was recognised by making the finals at this year’s HSJ Partnership Awards.
How many organisations/clients currently utilise the service/solution across the UK?
119 hospitals currently utilise this service
Is there anything you would like to make delegates aware of ahead of the NHS Long Term Plan 2020 conference on 29th April?
Norgine were encouraged by the contents of the Long-Term Plan. Our experience in the ITP has made us acutely aware of the benefits that strong industry/NHS partnerships can bring to all stakeholders in the health care system. Critically patients benefit when industry and the NHS partner well.
Our portfolio has the potential to help patients, the NHS and providers.
What do you feel are the key points delegates need to digest when considering a partnership with Norgine?
We have already demonstrated that we can partner with NHSE and have done so with great success. We have a portfolio of innovative medicines, with great potential for uptake to increase. Ultimately, this will be to the benefit of patients.
If you would like to learn more about Norgine please visit https://www.norgine.com/